DK1125577T3 - Væskeformige medikamentindföringspræparater - Google Patents

Væskeformige medikamentindföringspræparater

Info

Publication number
DK1125577T3
DK1125577T3 DK01111735T DK01111735T DK1125577T3 DK 1125577 T3 DK1125577 T3 DK 1125577T3 DK 01111735 T DK01111735 T DK 01111735T DK 01111735 T DK01111735 T DK 01111735T DK 1125577 T3 DK1125577 T3 DK 1125577T3
Authority
DK
Denmark
Prior art keywords
controlled release
gelatinous
compositions
liquid
drug delivery
Prior art date
Application number
DK01111735T
Other languages
English (en)
Inventor
Gerald L Yewey
Nancy L Krinick
Richard L Dunn
Michael L Radomsky
Gerbrand Brouwer
Arthur J Tipton
Original Assignee
Qlt Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22843701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1125577(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Qlt Usa Inc filed Critical Qlt Usa Inc
Application granted granted Critical
Publication of DK1125577T3 publication Critical patent/DK1125577T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/937—Utility as body contact e.g. implant, contact lens or I.U.D.
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/774—Exhibiting three-dimensional carrier confinement, e.g. quantum dots
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Fluid-Pressure Circuits (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK01111735T 1994-04-08 1995-03-27 Væskeformige medikamentindföringspræparater DK1125577T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22514094A 1994-04-08 1994-04-08
EP95914202A EP0754032B1 (en) 1994-04-08 1995-03-27 Liquid delivery compositions

Publications (1)

Publication Number Publication Date
DK1125577T3 true DK1125577T3 (da) 2006-06-19

Family

ID=22843701

Family Applications (2)

Application Number Title Priority Date Filing Date
DK95914202T DK0754032T3 (da) 1994-04-08 1995-03-27 Flydende frigivelsessammensætninger
DK01111735T DK1125577T3 (da) 1994-04-08 1995-03-27 Væskeformige medikamentindföringspræparater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK95914202T DK0754032T3 (da) 1994-04-08 1995-03-27 Flydende frigivelsessammensætninger

Country Status (13)

Country Link
US (3) US5759563A (da)
EP (2) EP1125577B1 (da)
JP (2) JP4259610B2 (da)
KR (1) KR100374098B1 (da)
AT (2) ATE317690T1 (da)
BR (2) BR9507313B8 (da)
CA (2) CA2187353C (da)
DE (2) DE69524398T2 (da)
DK (2) DK0754032T3 (da)
ES (2) ES2171186T3 (da)
NZ (1) NZ283282A (da)
PT (1) PT754032E (da)
WO (1) WO1995027481A1 (da)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236700T3 (es) * 1993-11-19 2005-07-16 Janssen Pharmaceutica N.V. 1,2-benzazoles microencapsulados.
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US20030077317A1 (en) * 1996-06-25 2003-04-24 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
US20060025328A1 (en) * 1997-05-28 2006-02-02 Burns Patrick J Compositions suitable for controlled release of the hormone GnRH and its analogs
DE59813940D1 (de) 1997-06-05 2007-04-19 Roland Bodmeier Multiphasensystem
AUPO907697A0 (en) 1997-09-09 1997-10-02 Day, Robert Edward Chemical supplementation of bone
US6054421A (en) * 1997-09-23 2000-04-25 Scimed Life Systems, Inc. Medical emulsion lubricant
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
ZA9811376B (en) * 1997-12-12 1999-06-28 Expression Genetics Inc Biodegradable mixed polymeric micelles for gene delivery
US6410057B1 (en) * 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
US6733767B2 (en) * 1998-03-19 2004-05-11 Merck & Co., Inc. Liquid polymeric compositions for controlled release of bioactive substances
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US7128927B1 (en) * 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US7790192B2 (en) * 1998-08-14 2010-09-07 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6368658B1 (en) * 1999-04-19 2002-04-09 Scimed Life Systems, Inc. Coating medical devices using air suspension
EP1949890A3 (en) * 1999-06-04 2011-05-18 ALZA Corporation Implantable gel compositions and method of manufacture
CN100370967C (zh) * 1999-06-04 2008-02-27 阿尔萨公司 埋植凝胶组合物及其制备方法
ES2273702T3 (es) 1999-06-11 2007-05-16 Cytyc Corporation Composicion liquido en gel para cartografiar un conducto galactoforo mamario antes de la escxision quirurgica del conducto o de otro tejido mamario.
US6358197B1 (en) * 1999-08-13 2002-03-19 Enteric Medical Technologies, Inc. Apparatus for forming implants in gastrointestinal tract and kit for use therewith
US6755811B1 (en) * 1999-08-25 2004-06-29 Corazon Technologies, Inc. Methods and devices for reducing the mineral content of a region of non-intimal vascular tissue
WO2001026704A2 (en) * 1999-10-12 2001-04-19 Yehuda Yarmut Targeted drug activation
US6331540B1 (en) 1999-11-01 2001-12-18 Alcon Universal Ltd. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
KR100416242B1 (ko) * 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
WO2001047501A1 (en) 1999-12-29 2001-07-05 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
AU2599501A (en) * 1999-12-29 2001-07-09 Advanced Cardiovascular Systems Inc. Device and active component for inhibiting formation of thrombus-inflammatory cell matrix
DE50112157D1 (de) 2000-01-11 2007-04-19 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
US7097855B1 (en) 2000-01-31 2006-08-29 Massachusetts Institute Of Technology Transdermal thermal polymerization
KR20020081687A (ko) 2000-02-17 2002-10-30 쓰리엠 이노베이티브 프로퍼티즈 캄파니 예비성형된 생분해성 중합체 조성물을 사용하는 전달시스템과 방법들
US7193007B2 (en) * 2000-03-15 2007-03-20 Yu-Ling Cheng Environment responsive gelling copolymer
US7160931B2 (en) * 2000-03-15 2007-01-09 Yu-Ling Cheng Thermally reversible implant and filler
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
EP1274459B1 (en) 2000-04-19 2005-11-16 Genentech, Inc. Sustained release formulations comprising growth hormone
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
ES2225573T3 (es) 2000-07-28 2005-03-16 Alcon, Inc Composiciones farmaceuticas que contienen tobramicina y goma xantana.
DE60131177T2 (de) * 2000-09-06 2008-08-07 AP Pharma, Inc., Redwood Abbaubare polyacetal-polymere
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK1372729T3 (da) * 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US20030152630A1 (en) * 2001-05-11 2003-08-14 Ng Steven Y. PEG-POE, PEG-POE-PEG, and POE-PEG-POE block copolymers
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US7318931B2 (en) * 2001-06-21 2008-01-15 Genentech, Inc. Sustained release formulation
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
AU2002341959A1 (en) * 2001-10-04 2003-04-14 Case Western Reserve University Drug delivery devices and methods
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
NZ533436A (en) * 2001-11-14 2007-10-26 Alza Corp Catheter injectable depot compositons and uses thereof
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US6537985B1 (en) * 2001-11-30 2003-03-25 Phoenix Scientific, Inc. Antibiotic formulation and a method of making this formulation
US7479535B2 (en) * 2002-02-25 2009-01-20 Guilford Pharmaceuticals, Inc. Phosphorous-containing compounds with polymeric chains, and methods of making and using the same
EP1344538A1 (en) 2002-03-14 2003-09-17 Degradable Solutions AG Porous biodegradable implant material and method for its fabrication
KR100496353B1 (ko) * 2002-04-15 2005-06-20 서울산업대학교 산학협력단 약물방출 능을 가진 생분해성 고분자를 이용한 조직공학용생분해성 고분자 지지체 및 그의 제조 방법
US7432245B2 (en) * 2002-06-07 2008-10-07 Abbott Laboratories Inc. Pharmaceutical formulation comprising a peptide angiogenesis inhibitor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AR039729A1 (es) 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7678827B2 (en) 2002-07-15 2010-03-16 Alcon, Inc. Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2002359397B2 (en) * 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
JP2006508127A (ja) * 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
US7045589B2 (en) * 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
JP4865330B2 (ja) * 2002-12-13 2012-02-01 デュレクト コーポレーション 経口ドラッグデリバリーシステム
EP1622540A4 (en) * 2003-03-11 2009-12-30 Qlt Usa Inc FORMULATIONS FOR CELL-PLAN-DEPENDENT CANCER
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
US20040215335A1 (en) * 2003-04-25 2004-10-28 Brin David S. Methods and apparatus for treatment of aneurysmal tissue
US20050079202A1 (en) * 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US9289195B2 (en) * 2003-06-04 2016-03-22 Access Closure, Inc. Auto-retraction apparatus and methods for sealing a vascular puncture
US7331979B2 (en) * 2003-06-04 2008-02-19 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
WO2004110511A1 (en) * 2003-06-19 2004-12-23 Coloplast A/S A wound care device
TWI367103B (en) 2003-06-26 2012-07-01 Psivida Inc Bioerodible sustained release drug delivery systems
DE602004016995D1 (de) 2003-06-26 2008-11-20 Control Delivery Sys Inc In-situ gelierendes arzneimittelabgabesystem
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050245876A1 (en) * 2003-12-24 2005-11-03 Accessclosure, Inc. Apparatus and methods for facilitating access through a puncture including sealing compound therein
US20070060950A1 (en) * 2003-12-24 2007-03-15 Farhad Khosravi Apparatus and methods for delivering sealing materials during a percutaneous procedure to facilitate hemostasis
US20050149117A1 (en) * 2003-12-24 2005-07-07 Farhad Khosravi Apparatus and methods for delivering sealing materials during a percutaneous procedure to facilitate hemostasis
CA2552241C (en) * 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ， インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
CA2552758A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
US7976847B2 (en) 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US8048086B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US9238127B2 (en) 2004-02-25 2016-01-19 Femasys Inc. Methods and devices for delivering to conduit
US8048101B2 (en) 2004-02-25 2011-11-01 Femasys Inc. Methods and devices for conduit occlusion
US7829105B2 (en) * 2004-03-02 2010-11-09 Nanotherapeutics, Inc. Compositions for repairing bone
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8163030B2 (en) 2004-05-06 2012-04-24 Degradable Solutions Ag Biocompatible bone implant compositions and methods for repairing a bone defect
BRPI0511807C8 (pt) * 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
AU2005271700B2 (en) * 2004-07-12 2010-11-11 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
ES2293193T5 (es) 2004-07-13 2012-06-13 Bayer Schering Pharma Oy Sistema de suministro retardado con descarga inicial controlada
WO2006078320A2 (en) 2004-08-04 2006-07-27 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
US8980300B2 (en) 2004-08-05 2015-03-17 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
WO2006026504A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Mucoadhesive oral formulations of high permeability, high solubility drugs
US8348971B2 (en) * 2004-08-27 2013-01-08 Accessclosure, Inc. Apparatus and methods for facilitating hemostasis within a vascular puncture
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
AU2005287175B2 (en) 2004-09-17 2011-12-01 Durect Corporation Sustained local anesthetic composition containing preferably a sugar ester such as SAIB
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
AU2005302484A1 (en) * 2004-10-28 2006-05-11 Microchips, Inc. Orthopedic and dental implant devices providing controlled drug delivery
US8262693B2 (en) 2004-11-05 2012-09-11 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
ES2528720T3 (es) * 2004-11-10 2015-02-12 Tolmar Therapeutics, Inc. Sistema de suministro de polímero estabilizado
CA2526541C (en) * 2004-12-01 2013-09-03 Tyco Healthcare Group Lp Novel biomaterial drug delivery and surface modification compositions
US8263105B2 (en) * 2004-12-01 2012-09-11 Tyco Healthcare Group Lp Biomaterial drug delivery and surface modification compositions
WO2006071208A1 (en) * 2004-12-23 2006-07-06 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US8137664B2 (en) * 2005-02-02 2012-03-20 Sdgi Holdings, Inc. Method and kit for repairing a defect in bone
CN101370634A (zh) * 2005-02-16 2009-02-18 亚历山大·R·瓦卡若 供植入与药物传递的再吸收中空装置
CA2498623A1 (en) * 2005-02-18 2006-08-18 Qlt Inc. Treatment of onychomycosis
US20060189958A1 (en) * 2005-02-21 2006-08-24 Talton James D Inverted cannula for use in reconstituting dry material in syringes
US8002742B2 (en) * 2005-04-22 2011-08-23 Accessclosure, Inc. Apparatus and methods for sealing a puncture in tissue
US7806856B2 (en) * 2005-04-22 2010-10-05 Accessclosure, Inc. Apparatus and method for temporary hemostasis
WO2007001624A2 (en) * 2005-06-28 2007-01-04 Microchips, Inc. Medical and dental implant devices for controlled drug delivery
US20070005130A1 (en) * 2005-06-29 2007-01-04 Thierry Glauser Biodegradable polymer for coating
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
BRPI0614537A2 (pt) 2005-08-08 2017-06-06 Cytyc Corp método para aumentar a distância entre a superfície externa e tecido próxima a um local de extração cirúrgica e tecido corporal sensível e para aumentar a distância entre uma cavidade deixada por remoção cirúrgica de um tumor e uma pele do paciente
US8362086B2 (en) 2005-08-19 2013-01-29 Merial Limited Long acting injectable formulations
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8658210B2 (en) 2006-04-17 2014-02-25 Advanced Cardiovascular Systems, Inc. Polyesteramide platform for site specific drug delivery
US20070264338A1 (en) * 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
US20070265329A1 (en) * 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264339A1 (en) * 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
MX2009000434A (es) 2006-07-11 2009-01-29 Qps Llc Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos.
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US8936780B2 (en) * 2006-08-30 2015-01-20 Advanced Cardiovascular Systems, Inc. Stimuli responsive polyester amide particles
EP2077765A2 (en) 2006-09-13 2009-07-15 Accessclosure, Inc. Apparatus for sealing a vascular puncture
US8076448B2 (en) * 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
FI3660073T3 (fi) 2007-02-15 2023-09-11 Tolmar International Ltd Matalan purskeen poly(laktidi-ko-glykolidi)
EP2167069B1 (en) 2007-05-23 2011-10-26 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
TW200846031A (en) * 2007-05-25 2008-12-01 Shu-Yi Lin Drug delivery system and the preparing method thereof
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US20090004243A1 (en) 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
US7993367B2 (en) * 2007-09-28 2011-08-09 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
WO2009051701A2 (en) * 2007-10-15 2009-04-23 Wake Forest University Health Sciences Methods and compositions for printing biologically compatible nanotube composites of autologous tissue
JP2011502582A (ja) * 2007-11-02 2011-01-27 インセプト，エルエルシー 血管穿刺を塞ぐ装置および方法
WO2009064442A1 (en) * 2007-11-13 2009-05-22 Brookwood Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
US9364206B2 (en) 2008-04-04 2016-06-14 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
US8029533B2 (en) 2008-04-04 2011-10-04 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
CA2721927C (en) 2008-04-21 2014-01-28 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CA2723458C (en) 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
WO2009148579A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system
US8877225B2 (en) * 2008-06-03 2014-11-04 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
US20100120811A1 (en) 2008-07-17 2010-05-13 Peter Hanson Long-acting injectable analgesic formulations for animals
US20100016808A1 (en) * 2008-07-17 2010-01-21 Bioform Medical, Inc. Thin-Walled Delivery System
US10092580B2 (en) 2008-07-21 2018-10-09 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US10070888B2 (en) 2008-10-03 2018-09-11 Femasys, Inc. Methods and devices for sonographic imaging
US9554826B2 (en) 2008-10-03 2017-01-31 Femasys, Inc. Contrast agent injection system for sonographic imaging
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP3821817A3 (en) 2008-11-12 2021-11-03 Access Closure, Inc. Apparatus for sealing a vascular puncture
DE102008059201A1 (de) 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
AU2009324545A1 (en) * 2008-12-11 2011-06-30 A.P. Pharma, Inc. Methods for enhancing stability of polyorthoesters and their formulations
US9480643B2 (en) 2008-12-23 2016-11-01 Surmodics Pharmaceuticals, Inc. Implantable composites and implants comprising same
US8951546B2 (en) * 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US8974808B2 (en) 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US9415197B2 (en) * 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8685458B2 (en) 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
EP2427233B1 (en) * 2009-05-04 2016-12-21 Incept Llc Biomaterials for track and puncture closure
CN102573910B (zh) * 2009-06-12 2015-08-26 鹿特丹伊拉斯谟大学医疗中心 用于癌症光动力学治疗的靶向纳米光药物
US20110027331A1 (en) * 2009-07-29 2011-02-03 Warsaw Orthopedic, Inc. An implantable drug depot having a reversible phase transition material for treatment of pain and/or inflammation
JP2013514977A (ja) * 2009-12-16 2013-05-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 複数の物質の送達のための粒子
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
US8920921B2 (en) 2010-08-30 2014-12-30 Surmodics Pharmaceuticals, Inc. Terpolymer blends and their use as pressure-sensitive adhesives
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
JP6018504B2 (ja) * 2010-09-29 2016-11-02 株式会社クラレ アクリルアミド誘導体、高分子化合物およびフォトレジスト組成物
KR101411349B1 (ko) * 2010-12-24 2014-06-25 주식회사 삼양바이오팜 생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
EA027046B1 (ru) 2010-12-29 2017-06-30 Мединселл Биоразлагаемая композиция для доставки лекарственных средств, способ ее получения и ее применение
CA2824964C (en) 2011-01-19 2019-01-08 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US9820728B2 (en) 2011-01-19 2017-11-21 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
US8936635B2 (en) 2011-03-23 2015-01-20 Palmetto Pharmaceuticals Llc Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
US9386968B2 (en) 2011-05-11 2016-07-12 Access Closure, Inc. Apparatus and methods for sealing a vascular puncture
US20130095160A1 (en) * 2011-09-12 2013-04-18 Gautam S. GHATNEKAR Resorbable polystatin biomaterials
LT2782584T (lt) 2011-11-23 2021-09-10 Therapeuticsmd, Inc. Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2861348C (en) * 2012-01-23 2017-07-04 Allergan, Inc. Time released biodegradable or bioerodible microspheres or microparticles suspended in a solidifying depot-forming injectable drug formulation
US8721680B2 (en) 2012-03-23 2014-05-13 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US9757105B2 (en) 2012-03-23 2017-09-12 Accessclosure, Inc. Apparatus and methods for sealing a vascular puncture
US8906003B2 (en) 2012-06-05 2014-12-09 Cook Medical Technologies Llc Erodible embolization material for targeted tumor cryoablation
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
SI2877155T1 (sl) 2012-07-26 2021-04-30 Camurus Ab Opioidne formulacije
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
US10011671B2 (en) 2013-08-26 2018-07-03 Japan Science And Technology Agency Adhesive
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
CA2926358A1 (en) * 2013-10-08 2015-04-16 Ferring B.V. Microparticles comprising gnrh made by pgss
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
AU2015284048A1 (en) 2014-07-03 2017-02-16 Otonomy, Inc. Sterilization of ciprofloxacin composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US20160106804A1 (en) 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
JP2018521000A (ja) 2015-05-29 2018-08-02 シドネキシス，インク． Ｄ２ｏで安定化された医薬製剤
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3328898B8 (en) 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3004849C (en) 2015-11-16 2024-06-11 Georges Gaudriault A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2017100576A1 (en) 2015-12-11 2017-06-15 Otonomy, Inc. Ciprofloxacin otic composition and kits and method for using same
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
JP7034148B2 (ja) * 2016-06-10 2022-03-11 ニルバナ サイエンシーズ インク． 波長範囲が狭い蛍光発光のヒドロポルフィリンビーズ
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. GEL FORMULA FOR THE EAR FOR TREATING OTITIS EXTERNA
JP7074963B2 (ja) * 2017-01-31 2022-05-25 ヴェル インコーポレイテッド ゴナドトロピン放出ホルモン（ＧｎＲＨ）拮抗薬の長期放出のための組成物および方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
BR112020011774A2 (pt) 2017-12-18 2020-11-17 Foresee Pharmaceuticals Co., Ltd. composições farmacêuticas com duração de liberação selecionada
KR20200108873A (ko) 2018-01-09 2020-09-21 오토노미, 인코포레이티드 성장 인자 귀 제제
WO2019154895A1 (en) 2018-02-08 2019-08-15 Strekin Ag Gel formulation for preventing or treating hearing loss
CN114144224B (zh) 2019-03-26 2024-08-09 保科特纳洛克斯恩公司 药物合成物输送器械和方法
CA3141456A1 (en) 2019-05-27 2020-12-03 Tolmar International Limited Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022154463A1 (ko) * 2021-01-15 2022-07-21 랩인큐브 주식회사 금속유기 복합입자 및 금속유기 복합입자를 포함하는 조성물
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2024168024A1 (en) 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix organic solvent formulations
WO2024168022A2 (en) 2023-02-10 2024-08-15 Tolmar, Inc. Degarelix polymeric formulations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2155658A (en) * 1936-01-08 1939-04-25 Chemische Forschungs Gmbh Surgical and medical preparations
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US4450150A (en) * 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
DE2908794C2 (de) * 1978-03-09 1984-09-13 Japan Atomic Energy Research Institute, Tokio/Tokyo Verfahren zur Herstellung eines eine physiologisch aktive Substanz enthaltenden Polymerpräparates
US4265247A (en) * 1979-11-07 1981-05-05 Research Corporation Malic acid polymers
US4408023A (en) * 1980-11-12 1983-10-04 Tyndale Plains-Hunter, Ltd. Polyurethane diacrylate compositions useful for contact lenses and the like
DE3045135A1 (de) * 1980-11-29 1982-06-09 Sandoz-Patent-GmbH, 7850 Lörrach Pharmazeutische kompositionen enthaltende bioabbaubare polymere
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4631188A (en) * 1983-08-31 1986-12-23 S.K.Y. Polymers, Ltd. (Kingston Technologies) Injectable physiologically-acceptable polymeric composition
US4685883A (en) * 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
AU565354B2 (en) * 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
JPS62223112A (ja) * 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
US4780320A (en) * 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) * 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5227157A (en) * 1986-10-14 1993-07-13 Board Of Regents, The University Of Texas System Delivery of therapeutic agents
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US5013553A (en) * 1987-06-30 1991-05-07 Vipont Pharmaceutical, Inc. Drug delivery devices
US4912141A (en) * 1987-07-28 1990-03-27 Kronman Joseph H Fibrous and cartilaginous tissue replacement
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
IT1226800B (it) * 1988-09-16 1991-02-19 Prodotti Formenti Composizioni farmaceutiche orali contenenti sali di destrorfano.
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
NZ239370A (en) * 1990-08-22 1994-04-27 Merck & Co Inc Bioerodible implantable controlled release dosage form comprising a poly(ortho ester) or a polyacetal with an active agent incorporated into the chain backbone
US5238714A (en) * 1990-10-02 1993-08-24 Board Of Regents, The University Of Texas System Efficient microcapsule preparation and method of use
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
JPH04173746A (ja) * 1990-11-07 1992-06-22 Unitika Ltd 徐放性機能を有する薬剤・ポリマー複合体
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5326568A (en) * 1991-05-03 1994-07-05 Giampapa Vincent C Method of tissue-specific delivery
US5176907A (en) * 1991-08-13 1993-01-05 The Johns Hopkins University School Of Medicine Biocompatible and biodegradable poly (phosphoester-urethanes)
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法

Also Published As

Publication number Publication date
EP0754032A1 (en) 1997-01-22
MX9604634A (es) 1997-11-29
DK0754032T3 (da) 2002-04-02
EP1125577A3 (en) 2003-01-08
JPH09511741A (ja) 1997-11-25
US5759563A (en) 1998-06-02
ES2258495T3 (es) 2006-09-01
PT754032E (pt) 2002-05-31
AU2129495A (en) 1995-10-30
ES2171186T3 (es) 2002-09-01
NZ283282A (en) 1998-01-26
DE69534780D1 (de) 2006-04-20
CA2582666A1 (en) 1995-10-19
EP1125577B1 (en) 2006-02-15
ATE209907T1 (de) 2001-12-15
JP2009029821A (ja) 2009-02-12
KR100374098B1 (ko) 2003-06-09
BR9507313A (pt) 1997-10-07
US5744153A (en) 1998-04-28
JP4259610B2 (ja) 2009-04-30
BR9507313B8 (pt) 2016-06-07
EP1125577A2 (en) 2001-08-22
KR970702029A (ko) 1997-05-13
CA2187353A1 (en) 1995-10-19
DE69524398D1 (de) 2002-01-17
EP0754032B1 (en) 2001-12-05
AU684931B2 (en) 1998-01-08
WO1995027481A1 (en) 1995-10-19
JP4974987B2 (ja) 2012-07-11
US5780044A (en) 1998-07-14
CA2187353C (en) 2007-05-22
DE69534780T2 (de) 2006-10-05
DE69524398T2 (de) 2002-07-18
CA2582666C (en) 2010-05-25
ATE317690T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
DK1125577T3 (da) Væskeformige medikamentindföringspræparater
CA2235919A1 (en) Non-polymeric sustained release delivery system
DK1586309T6 (da) Polymere indgivelsesformuleringer af leuprolid med forbedret virkning
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
DE59610355D1 (de) Medizinisches implantat
DE69623087D1 (de) Brausemittel und dessen Herstellung
DE69721481D1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
FI913410A (fi) Kontinuerligt frigoerande farmaceutiska kompositioner.
MY132179A (en) Improved formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
DE69634009D1 (de) Implantierbare vorrichtung zur kontrollierten abgabe von arzneimitteln unmittelbar an einen inneren teil des körpers
DE69628783D1 (de) Hydrogelbildende, selbst-solvatisierende, absorbierbare Polyestercopolymere sowie Verfahren zu deren Verwendung
FI970934A0 (fi) Implantoitava valukappale vaikuttavien aineiden annostelemiseksi kasveihin
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel